Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice

Neoplasma

Volumn 48, Issue 5, 2001, Pages 358-361

  Dabrowska, A ^a   Giermasz, A ^a   Golab, J ^a   Jakobisiak M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Interferon alpha; Interleukin 12; Melanoma; Mice

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; MELANOMA; MOUSE; NONHUMAN; TREATMENT OUTCOME;

EID: 0035209760     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. The combination of antiangiogenic agents to inhibit the primary tumor growth and metastasis
2. Macrophage role in the anti-prostate cancer response to one class of anti-angiogenic agents
3. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice
4. IL-12 regulates VEGF and MMPs in a murine breast cancer model
5. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration
6. Interferon-α-2a therapy for life-threatening hemangiomas of infancy
7. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses
8. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor)
9. Potentiated antitumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo
10. Antitumor effects of interleukin 12 in pre-clinical and early clinical studies (Review)
11. Potentiated antitumor effectiveness of combined immuno-chemotherapy with interleukin-12 and 5-Fluorouracil of L12 10 leukemia in vivo
12. Cytokine therapeutics: Lessons from interferon-α
13. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice
14. Subtherapeutic doses of IL-15 augment the antitumor effect of IL-12 in a B16F10 melanoma model in mice
15. Retinoic acid and interferon α act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma
16. Natural killer cell stimulatory factor (Interleukin 12 [IL12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells
17. Combination cytokine immunotherapy with tumor necrosis factor α, interleukin 2 and α-interferon and its synergistic antitumor effects in mice
18. Combination of interleukin-12 and interferon α gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma
19. Interferon-α in the treatment of AIDS-related Kaposi's sarcoma
20. Regression of human breast cancer xenografts in response to intralesional treatment with interferons α and γ potentiated by tumor necrosis factor
21. + T lymphocytes, and NK cells
22. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
23. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
24. Effects of interferons and other cytokines on tumors in animals: A review
25. Inhibition of angiogenesis in vivo by interleukin 12
26. Effective chemoimmunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin